We are a precision oncology company focused on the discovery, development and commercialization of covalent small molecule programs. We are creating an entirely new generation of molecular scaffolds, targeting genetically defined diseases. We believe that covalent small molecules have the potential to address the key limitations of existing reversible therapeutics as well as to treat diseases where targeted therapies are not yet approved. The following table summarizes our product candidate pipeline. We own full worldwide development and commercialization rights to all of our programs.
All our assets are in house designed, developed, and wholly owned by Biomea Fusion Inc.